DENTSPLY SIRONA director buys 9,985.022 shares
DENTSPLY SIRONA Inc. director Brian T. Gladden reported an open-market purchase of 9,985.022 shares of common stock on June 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
DENTSPLY SIRONA Inc. director Brian T. Gladden reported an open-market purchase of 9,985.022 shares of common stock on June 15, 2026. The weighted average purchase price was $10.015 per share, based on multiple trades between $10.015 and $10.0156. Following this transaction, he directly owns 61,848.544 shares of the company’s common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 9,985.022 | $10.015 | $100K |
Footnotes (1)
- F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.015 to 10.0156, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Key Figures
Key Terms
open-market purchase financial
weighted average price financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DENTSPLY SIRONA (XRAY) disclose for Brian T. Gladden?
Was Brian T. Gladden’s DENTSPLY SIRONA (XRAY) transaction a purchase or a sale?
Did the DENTSPLY SIRONA (XRAY) insider trade involve derivatives or only common stock?
AI-generated analysis. How Rhea-AI works. Not financial advice.